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Background: The Burkholderia cenocepacia lipid A is hypoacylated.
Results: Aminoarabinose residues in lipid A contribute to Burkholderia lipid A binding to the TLR4MD-2 complex.
Conclusion: A novel mode of Burkholderia lipopolysaccharide-TLR4MD-2 interactions promotes inflammation.
Significance:Modifications of the lipid A structure enhance proinflammatory responses of hypoacylated lipopolysaccharide.
Lung infection by Burkholderia species, in particular Burk-
holderia cenocepacia, accelerates tissue damage and increases
post-lung transplant mortality in cystic fibrosis patients. Host-
microbe interplay largely depends on interactions between
pathogen-specificmolecules and innate immune receptors such
asToll-like receptor 4 (TLR4), which recognizes the lipidAmoi-
ety of the bacterial lipopolysaccharide (LPS). The human
TLR4myeloid differentiation factor 2 (MD-2) LPS receptor
complex is strongly activated by hexa-acylated lipid A and
poorly activated by underacylated lipid A. Here, we report that
B. cenocepacia LPS strongly activates human TLR4MD-2
despite its lipid A having only five acyl chains. Furthermore, we
show that aminoarabinose residues in lipid A contribute to
TLR4-lipidA interactions, and experiments in amousemodel of
LPS-induced endotoxic shock confirmed the proinflammatory
potential of B. cenocepacia penta-acylated lipid A. Molecular
modeling combined with mutagenesis of TLR4-MD-2 interactive
surfaces suggests that longer acyl chains and the aminoarabinose
residues in the B. cenocepacia lipid A allow exposure of the fifth
acyl chain on the surface ofMD-2 enabling interactionswithTLR4
and its dimerization. Our results provide a molecular model for
activation of the human TLR4MD-2 complex by penta-acylated
lipidAexplaining theability ofhypoacylatedB. cenocepaciaLPS to
promote proinflammatory responses associated with the severe
pathogenicity of this opportunistic bacterium.
A central theme in innate immunity involves recognition of
conserved microbial molecules (pathogen-associated molecu-
lar patterns) by surface receptors expressed on phagocytic cells
(1, 2). Pathogen recognition triggers cell signaling cascades,
leading to activation of transcription factors such as nuclear
factor-B (NF-B) and interferon regulatory factors, which in
turn stimulate production of inflammatory cytokines (e.g.
TNF-, IL-1, and type I interferons) (3). Lipopolysaccharide
(LPS), the major component of the Gram-negative bacterial
outer membrane, elicits potent innate immune responses
through interactions with a receptor complex composed of
Toll-like receptor 4 (TLR4)5 and myeloid differentiation factor
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2 (MD-2) (4). Depending on the amount and chemical nature of
LPS released from the pathogen, TLR4MD-2 recognition stim-
ulates a protective immune response or leads to uncontrolled
inflammation associated with high mortality (5, 6). LPS is a
complex glycolipid consisting of three distinct domains (see
Fig. 1) (7): lipid A, core oligosaccharide, and in many bacteria
a repeating polysaccharide moiety known as the O-antigen
(8–10). Lipid A, composed of an acylated glucosamine disac-
charide backbone, is the LPS moiety recognized by the
TLR4MD-2 receptor complex. Lipid A bioactivity depends on
its chemical structure. The number and distribution of acyl
chains and the presence of the phosphate groups in the diglu-
cosamine backbone determine the agonistic and antagonistic
activities of lipid A (11–19).Most enteric bacteria such as Esch-
erichia coli produce hexa-acylated bisphosphorylated lipid A,
which has the highest cytokine-inducing capacity in mammals.
In contrast, tetra-acylated lipid A (such as lipid IVA) and most
penta-acylated lipid A forms lack activity on human cells (19,
20).
Lipid A interacts with a hydrophobic pocket formed by two
anti-parallel -sheets of MD-2 mediating the dimerization and
activation of the TLR4MD-2 complex (19, 21). The MD-2
hydrophobic pocket can accommodate up to five acyl chains.
For agonistic hexa-acylated E. coli lipid A, five acyl chains are
buriedwithin the pocket, whereas the sixth chain lies on a chan-
nel of theMD-2 surface, building a hydrophobic region and the
dimerization interface required for interaction with the TLR4
partner (referred to here as TLR4*). This arrangement enables
hydrophobic interactions bridging the TLR4MD-2LPS het-
erodimer and promoting the juxtaposition of the intracellular
domains, leading to activation of signal transduction (18, 22).
By contrast, antagonist lipid IVA binds to humanMD-2 with all
four acyl chains completely buried in the hydrophobic pocket
precluding dimerization and subsequent activation (23). Simi-
larly, many penta-acylated lipid As act as an antagonist of
human TLR4MD-2 (24, 25). In contrast, lipid IVA can activate
the murine TLR4MD-2 complex (26).
Bacteria regulate the degree of lipid A acylation in response
to environmental conditions. For example, Pseudomonas
aeruginosa strains possess penta-acylated lipid A but can pro-
duce hexa-acylated lipid A during infection in cystic fibrosis
(CF) patients (27), gaining the ability to elicit stronger inflam-
mation. Intriguingly, the non-CF pathogen Porphyromonas
gingivalis produces a high heterogeneous LPS lipid A whose
penta-acylated isoform potently activates the NF-B pathway
in human gingival fibroblasts in a similar manner to the E. coli
LPS (28). Therefore, the molecular mechanisms underlying
TLR4 dimerization and activation cannot always be predicted
based on the E. coli lipid A-TLR4MD-2 paradigm.
Burkholderia cenocepacia is an opportunisticGram-negative
bacterium causing serious infections in CF patients (29).
Understanding how B. cenocepacia infection elicits inflamma-
tion is crucial to finding new ways to improve treatment of
infected CF patients. The structure of the B. cenocepacia LPS
(LPSBC) was described previously (30). The lipid A moiety of
LPSBC consists of a mixture of penta-acylated and tetra-acy-
lated, bisphosphorylated diglucosamine backbone with two
4-amino-4-deoxy-L-arabinose (L-Ara4N) residues linked by
phosphodiester linkages (see Fig. 1) (30). The acyl chains are
made of 3-(R)-hydroxyhexadecanoic acid C16:0 (3-OH), 3-(R)-
hydroxytetradecanoic acid C14:0 (3-OH), and hydroxytetrade-
canoic acid C14:0 (see Fig. 1) (30). The L-Ara4N decoration of
lipid A is essential for B. cenocepacia viability (31) and repre-
sents the major determinant of resistance to cationic antimi-
crobial peptides (30, 31). The structural features of LPSBC sug-
gest that the molecule would be a very poor TLR4MD-2
complex agonist compared with the prototypic enterobacterial
LPS. In contrast, several studies show that LPSBC as well as
biological and synthetic lipid A analogues is highly proinflam-
matory (32–36). Therefore, the current model for binding/ac-
tivation of human TLR4MD-2 complex cannot explain why
LPSBC is proinflammatory. In this work, we investigated the
molecular basis of the mechanism of LPSBC recognition and
report for the first time that acyl chains longer than those in
enterobacterial lipid A together with the L-Ara4N residues
allow B. cenocepacia lipid A (LABC) to fit into the binding
pocket ofMD-2 in amanner that promotes TLR4 dimerization,
leading to activation of inflammatory responses in cellular and
animal models.
Experimental Procedures
LPS Extraction and Purification—LPS was prepared from B.
cenocepacia strains MH71 and MH75 (30). Both strains are
isogenic derivatives of the K56-2 clinical isolate and contain a
deletion of thewbiF gene that eliminatesO-antigen production.
MH75 also has a deletion removing genes involved in UDP-L-
Ara4N synthesis and therefore cannot produce LPS with
L-Ara4N residues (LPSBCAra). Both MH71 and MH75 also
carry a suppressormutation in the LPS transport gene lptG that
allows for the transport of LPS devoid of L-Ara4N to the bacte-
rial outer membrane (30). The P. aeruginosa RP73 clinical iso-
late was obtained from a chronically infected CF patient and
kindly provided by Prof. Burkhard Tu¨mmler (Klinische
Forschergruppe, Medizinische Hochschule Hannover, Han-
nover, Germany) (37, 38). Strains were plated on trypticase soy
agar plates and cultured in trypticase soy broth at 37 °C. For
large scale LPS purification, bacteria were treatedwith hot phe-
nol/water (39). After extensive dialysis against distilled water,
the extracted phases were subjected to enzymatic digestions to
remove nucleic acids and protein contaminants. Water and
phenol fractions were analyzed by 13.5% SDS-PAGE and silver
staining (40). The LPS fraction was exclusively found in the
water phase.
Isolation of Lipid A—Lipid A was obtained by hydrolysis of
the LPS with 100 mM sodium acetate buffer, pH 4.4 (100 °C for
3 h). The solution was extracted three times with CHCl3/
MeOH/H2O (100:100:30, v/v/v) and centrifuged (4 °C at
5000 g for 15 min). The organic phase contained lipid A, and
thewater phase contained the core oligosaccharide. The former
was further purified through several washes with distilled water
and then lyophilized. The lipid A and core oligosaccharide
structures of strains K56-2, MH71, and MH75 were character-
ized elsewhere (Fig. 1) (30, 41).
Mouse Endotoxic Studies—Animal studies were conducted
according to protocols approved by the San Raffaele Scientific
Institute (Milan, Italy) Institutional Animal Care andUseCom-
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mittee and adhered strictly to the Italian Ministry of Health
guidelines for the use and care of experimental animals. Efforts
were made to minimize the number of animals used and their
suffering. C57BL/6 mice (20–22 g; male; Charles River) were
challenged via intraperitoneal injection with 300 g/mouse
LPS fromE. coli andP. aeruginosaRP73, LPSBC, andLPSBCAra.
Control mice were challenged with sterile saline solution. Five
hours after treatment, mice were sacrificed by CO2 administra-
tion, and blood was collected from heart puncture. The blood
clot was left at room temperature for 15–30 min. The clot was
removed by centrifugation at 2000 g for 10 min at 4 °C. Sera
were collected and stored at 20 °C. TNF- concentration in
sera was determined by ELISA (R&D Systems) according to the
manufacturer’s instructions using antibody pairs and recombi-
nant standards from R&D Systems.
Human Embryonic Kidney (HEK) 293 Cell Activation and
Luciferase Reporter Assays—Expression plasmids containing
sequences of human TLR4 andMD-2 and the pELAM-1 firefly
luciferase plasmidwere a gift fromDr.C. Kirschning (Technical
University of Munich, Munich, Germany). Expression plasmid
containing sequence of mouse TLR4 was purchased from Invi-
voGen. Expression plasmid formouseMD-2was a gift fromDr.
Y. Nagai (University of Tokyo, Tokyo, Japan). TheRenilla lucif-
erase phRL-TK plasmid was purchased from Promega.
Recombinant MD-2 genes were cloned into pEF-BOS with
FLAG and His tags on the C terminus. Recombinant TLR4
genes were cloned into pUNO with a C-terminal HA tag.
Transfection reagent JetPEI was purchased from Polyplus
Transfection (France) and was used according to the manufac-
turer’s instructions. The HEK293 cells were provided by Dr.
J. Chow (Eisai Research Institute, Andover, MA) and grown in
DMEM supplemented with 10% FBS. TheMD-2 mutants were
made using the QuikChange site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s instructions. All
plasmids were sequenced to confirm the appropriate muta-
tions. For the NF-B-luciferase reporter assay, HEK293 cells
were seeded in 96-well plates at 3  104 cells/well and incu-
bated overnight in a humidified atmosphere (5% CO2) at
37 °C. The next day when cells were 60–80% confluent, they
were co-transfected with the plasmids for MD-2 (10 ng),
TLR4 (1 ng), NF-B-dependent luciferase (50 ng), and con-
stitutive Renilla luciferase (10 ng) using JetPEI transfection
reagent (all amounts are in ng/well). Cells were stimulated
6 h after transfection with endotoxin preparations. Cells
were lysed after 16 h of stimulation in 1 reporter assay lysis
buffer (Promega) and analyzed for reporter gene activities
using the Dual-Luciferase reporter assay system. Relative
luciferase units were calculated by normalizing the luciferase
activity of each sample with the constitutive Renilla activity
measured within the same sample.
Statistical Analysis—Results were expressed as mean S.D.
from experiments done in triplicate. Statistical calculations and
tests in vitro and in vivo were performed using Student’s t test
considering p 0.05 as the limit of statistical significance and a
p value of 0.001 as extremely significant.
FIGURE 1. Structure of B. cenocepacia LPS inner core and lipid A. B. cenocepacia lipid A is heterogeneous, being composed of a mixture of penta- and
tetra-acylated species (30, 40). Lipid A fatty acids are two 3-(R)-hydroxyhexadecanoic acids, two 3-(R)-hydroxytetradecanoic acids, and one tetradecanoic acid
(30, 40). The dotted lines indicate the non-stoichiometric substitution.
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MolecularModeling: Building andGeometryOptimization of
LPSBC and LPSBCAra—Three-dimensional coordinates were
built by Maestro (42). Molecular mechanics optimization (uni-
versal force field), semiempirical calculations (AM1), and den-
sity functional theory (B3LYP/6-31G*) were subsequently
applied using Gaussian 03 (43). Ammonium and carboxylic
acid groups were considered as ionized. Conformational anal-
ysis on DS1, DS2, and DS3 disaccharides was performed with
MacroModel (44). The parameterswere as follows:MM3* force
field and water solvent dielectric constant of 1.0. The charges
from the force fieldwere usedwith an extended cutoff. The best
conformers were selected, and from them,molecular dynamics
simulations (MDSs) with implicit water andMM3* as the force
field were performed using Schro¨dinger Maestro 9.3 and
Impact 5.8 (42, 45) (MM3* force field; dielectric constant, 80.0;
number of MDS steps, 100; time step (ps), 0.001).
The full three-dimensional structures of LABCAra, LABC,
and LPSBC were built with Maestro using optimized disaccha-
ride scaffolds obtained from the conformational analysis. Fatty
acid chains, DS6, and aminoarabinoses were optimized sepa-
rately using Gaussian 03 (B3LYP/6-31G*). The starting confor-
mation for lipid A optimization was obtained from E. coli lipid
A fromProteinData Bank code 3fxi. The full structure of LPSBC
was built by putting together core region disaccharides and
lipid A with five aliphatic chains. Final MDS of the geometry
was performed with implicit water by means of Impact (MM3*
force field; dielectric constant, 80.0; number ofMDS steps, 100;
time step (ps), 0.001). Three-dimensional structures of lipid A
molecules for validation were extracted from their correspond-
ing Protein Data Bank files (E. coli lipid A was obtained from
ProteinData Bank code 3fxi, andRe chemotype ofE. coli lipidA
was obtained from Protein Data Bank code 3vq2), refined with
the help of Maestro, and finally submitted toMDS with Impact
(MM3* force field and implicit water).
Molecular Modeling—For docking studies with MD-2 and
TLR4 proteins, three-dimensional coordinates from MD-2
protein were obtained from Protein Data Bank codes 3fxi
(humanMD-2) and 3vq2 (murineMD-2) and refined andmin-
imizedwith the Protein PreparationWizardmodule ofMaestro
using the AMBER force field (46). The TLR4 structure was
obtained from Protein Data Bank code 3fxi and treated follow-
ing the same procedure after removing water molecules and
any other non-standard residue.
Two different docking methodologies were used for docking
studies of LABCAra and LABC on MD-2: AutoDock and Aut-
oDock Vina. Although AutoDock is a widely used semiempiri-
cal docking method (47), the recently released AutoDock Vina
combines empirical and knowledge-based scoring functions
with good performance and reduced computing time (48). Each
ligand was docked into human andmurineMD-2 protein using
AutoDock 4.2 (49) and separately using AutoDock Vina 1.1.2
(48). For humanMD-2 (from Protein Data Bank code 3fxi), the
Autogrid grid point spacing was set at 0.375 Å; center coordi-
nates of the grid box were 29.00,7.00, and 17.875 (x, y, z); and
number of grid points in xyz was 41, 53, and 83. For murine
MD-2 (from Protein Data Bank code 3vq2), the Autogrid grid
point spacing was set at 0.375 Å and center coordinates of the
grid box were 27.50, 15.50, and 22.00 (x, y, z), leading to
75  40  60 (x, y, z) grid points. The best result from each
docking job with LABC was used as the starting geometry for
subsequent docking calculations. Different combinations of
allowed rotatable bonds were also considered for the ligands.
Docking calculations with AutoDock were performed using a
genetic algorithm (number of individuals in population, 150;
maximumnumber of energy evaluations, 2,500,000–5,000,000;
maximum number of generations, 27,000; number of top indi-
viduals to survive to next generation, 1; rate of gene mutation,
0.02; rate of crossover, 0.8; window size, 10;  parameter of
Cauchy distribution, 0.0;  parameter of Cauchy distribution,
1.0).When docking LPSBC, flexible dockingwas also performed
consideringAsp-101,Glu-120, andGlu-122 as flexible residues.
Docking calculations with AutoDock Vina were also per-
formed. Coordinates and dimensions of grid boxes, starting
geometries, and general methodology were the same as for
AutoDock.When docking LPSBC, flexible docking was also per-
formed considering Asp-101 as a flexible residue. Three-di-
mensional structures of the docked complexes were optimized
by MDS with Impact (implicit water and AMBER* force field).
For docking experiments studies of the B. cenocepacia LPS
core on human TLR4, we used AutoDock Vina 1.1.2. Torsional
bonds from the ligand were allowed to rotate. Ammonium
groups were considered as ionized. The grid box was built on
TLR4 from Protein Data Bank code 3fxi with grid center at
26.00,22.00, and 11.50 (x, y, z), number of grid points of 41
41  43 (x, y, z); and spacing of 0.375 Å. Final optimization of
the three-dimensional structure of the docked complex was
carried out by MDS with Impact (implicit water and AMBER*
force field).
The full complex of human TLR4MD-2 with B. cenocepacia
LPS core was built bymerging dockedMD-2LPS core complex
with docked LPS inner coreTLR4 using Protein Data Bank
code 3fxi as a template. The resulting structure was optimized
by MDS with implicit water (AMBER* force field). Coupling of
two TLR4MD-2LPSBC complexes was finally performed also
using Protein Data Bank code 3fxi as a template. The full three-
dimensional structure of the dimer complex was submitted to
MDS with implicit water and AMBER* force field (charges
from, force field; cutoff, extended; method, Polak-Ribie`re con-
jugate gradient; maximum iterations, 500; converge on, gradi-
ent; convergence threshold, 0.05). This final structure for the
TLR4MD-2LPSBC complex was used to generate the mutant
TLR4MD-2LPSBC complex (D294A, R322A, S415A*, and
S416A*) by changing the corresponding side chains to Ala side
chain. The resulting structure was submitted to MDS with
implicit water and AMBER* force field. Energy analysis was
performed by means of the MM-ISMSA method (50).
Results
LPS and Lipid A from B. cenocepacia Activate the
TLR4MD-2 Complex and Have Proinflammatory Activity in
Vivo—TLR4MD-2 activation by LPSBC and LABC was exam-
ined using the NF-B reporter luciferase assay in transiently
transfected HEK293 and HEK293T cells co-expressing murine
(mMD-2) or human MD-2 (hMD-2) and murine (mTLR4) or
human TLR4 (hTLR4). Initial results revealed that LPSBC and
LABC activate both human and mouse TLR4MD-2 complexes
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(Figs. 2 and 3, A and B). Because LABC possesses longer acyl
chains than those inE. coli lipidA and constitutively carries one
or two L-Ara4N residues, to further understand the structure-
function relationship of LPSBC, we utilized LPS from a mutant
strain lacking the ability to produce L-Ara4N (LPSBCAra).
NF-B reporter luciferase assays demonstrated that at 5 ng/ml
LPSBC and LPSBCAra induced activation of TLR4MD-2 com-
plexes (Fig. 2). Similar results were obtained in dose-response
experiments with purified LABC and LABCAra (at 5, 10, and
50 ng/ml) in cells co-expressing mTLR4mMD-2 and hTLR4
hMD-2 (Fig. 3,A and B, respectively), which also demonstrated
consistent agonistic activity at the lowest concentration of 5
ng/ml. However, NF-B activation by mouse (Fig. 3A) and
human (Fig. 3B) complexes was significantly lower with
LABCAra, suggesting that the L-Ara4Nmodification of the lipid
A plays a role in bioactivity of the LPS molecule.
Comparisons with NF-B activation elicited by synthetic
E. coli-type hexa-acylated lipid A revealed significantly less
activation by LPSBC andLABCAra (all at 50 ng/ml) (Fig. 3,A and
B). Lower activation by LPSBC and LPSBCAra could depend on
weaker binding to MD-2 or less efficient activation of TLR4.
Therefore, we examined whether LPSBC and LPSBCAra could
interfere with TLR4 signaling elicited by the E. coli LPS by a
competition assay in which HEK293 cells transfected with
hTLR4hMD-2were preincubatedwith LPSBC or LPSBCAra for
1 h and then restimulated with E. coli LPS for 4 h (Fig. 4). Pre-
incubation of cellswith 10ng/ml LPSBC followedby stimulation
by 1 ng/ml E. coli LPS revealed weaker NF-B activation than
that with E. coli LPS alone (p  0.05; Fig. 4). Interestingly, a
2-fold reduction in NF-B activation was evident in the case of
preincubation with 10 ng/ml LPSBCAra (p 0.01; Fig. 4). Fur-
thermore, a significant difference was found in activation by 10
ng/ml E. coli LPS alone compared with that obtained after pre-
incubation of cells with 100 ng/ml LPSBC and LPSBCAra (p 
0.01; Fig. 4). In contrast, this inhibitory effect was reduced by
increasing the concentration of the preincubated LPSBC and
LPSBCAra (100 ng/ml) added to the 1 ng/ml E. coli LPS; such
effect is probably due to the contribution of a weak activa-
tion of MD-2TLR4 by LPSBC and LPSBCAra. Collectively,
these results suggest that LPSBCAra efficiently binds to TLR4
MD-2 but is aweaker agonist comparedwith theE. coliLPS and
LPSBC.
The proinflammatory activity of LPS from B. cenocepacia
was assessed using an established in vivo model of endotoxic
shock. C57Bl/6 mice were challenged by intraperitoneal injec-
tion of LPS from E. coli and P. aeruginosa RP73 (a CF strain
expressing penta- and tetra-acylated lipid A (37)), LPSBC, and
LPSBCAra. After 5 h of treatment, TNF- levels in sera were
measured to evaluate proinflammatory and endotoxic poten-
tial. Compared with the saline solution control, penta-acylated
LPSBC induced robust TNF- production (LPSBC versus con-
trol, p  0.01; Fig. 5), whereas LPSBCAra induced 3-fold less
systemic release of TNF- in sera (LPSBCAra versus LPSBC, p
0.01; Fig. 5), suggesting a role for L-Ara4N residues in the
endotoxic LPS response in agreement with the in vitro
results (Fig. 2).
Identification of MD-2 Amino Acid Residues Involved in the
Interaction with LPSBC—To further investigate the molecular
recognition of LPSBC and LPSBCAra by TLR4MD-2, we con-
structed targeted hMD-2 and mMD-2 mutants that were co-
expressed with hTLR4 or mTLR4 in transfected HEK293 cells.
We focused on residues at the dimerization interface of the
MD-2 protein (22, 51). In particular, we examined Val-82
located in proximity to the pocket entrance at a loop between
FIGURE 2. LPSBC activates the murine and human TLR4MD-2 complexes. NF-B activation upon stimulation of HEK293 mTLR4mMD-2 and hTLR4hMD-2
after 6 hwith 5ng/ml LPSBC and LPSBCAra. Stimulation for 6 hwith E. coli LPSwasused as the control. Thedata arepooled from three independent experiments
done in triplicate. Bars indicate S.D.; significancewas calculated in comparisonwith stimulationwith E. coli LPS (*, p 0.05; **, p 0.01). Curly brackets indicate
significance calculated comparing LPSBC and LPSBCAra (*, p 0.05; **, p 0.01). NS, no stimulation.
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-strands 5 and 6. This region contains several conserved, sol-
vent-exposed hydrophobic residues that contribute to crucial
hydrophobic interactions in the activated receptor complex
(22). Val-82 was replaced by phenylalanine (V82F) to augment
the hydrophobic interactions of theMD-2lipidA complexwith
TLR4. In comparison with HEK293 cells transfected with
parental MD-2, hTLR4hMD-2 V82F led to increased activa-
tion upon stimulation with LPSBC and LPSBCAra, whereas
E. coli LPS activation was not significantly modified (Fig. 6).
This agrees with the notion that hexa-acylated lipid A provides
stronger hydrophobic interactions with TLR4, and therefore
increased hydrophobicity at position 82 augments the activa-
tion by penta-acylated LPS. No significant differences were
detected between stimulation with LPSBC and LABCAra on
hTLR4hMD-2 V82F. Hydrophobic interactions betweenmTLR4
mMD-2 and LA are expected to be similar to those involving
the hTLR4hMD-2 complex because nearly all the hydrophobic
residues are conserved (51). However, the electrostatic interac-
tions that contribute to receptor selectivity differ between
mMD-2 and hMD-2 proteins. Particularly, hMD-2 has a posi-
FIGURE 3. Lipid A activation of murine and human TLR4MD-2 complexes. A, NF-B activation upon stimulation of HEK293 mTLR4mMD-2 after 6 h with
LABC and LABCAra. Stimulations for 6 h with E. coli LPS, hexa-acylated lipid A, and lipid IVA were used as controls. The data are pooled from three independent
experiments done in triplicate. Bars indicate S.D.; significance was calculated in comparison with stimulation with hexa-acylated E. coli lipid A (*, p 0.05; **,
p 0.01; ***, p 0.001); curly brackets indicate significance calculated comparing LPSBC and LPSBCAra (**p 0.01). B, NF-B activation upon stimulation of
HEK293 hTLR4hMD-2 after 6 h with LABC and LABCAra. Stimulations for 6 h with E. coli LPS, hexa-acylated lipid A, and lipid IVA were used as controls. The data
are pooled from three independent experiments done in triplicate. Bars indicate S.D.; significance was calculated in comparison with stimulation with
hexa-acylated E. coli lipid A (*, p  0.05; ***, p  0.001); curly brackets indicate significance calculated comparing LPSBC and LPSBCAra (*, p  0.05). NS, no
stimulation.
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tively charged lysine at position 122 near the pocket entrance,
whereas mMD-2 has a negatively charged glutamic acid (51).
Moreover, hMD-2 has a positively charged lysine at position
125, whereas mMD-2 has a hydrophobic leucine (51). In the
complex, lysine residues 122 and 125 are close to the disaccha-
ride backbone of LA (52) and are important for the species-
FIGURE 4. B. cenocepacia LPSBCAra effects on the E. coli LPS agonist activity. The potential antagonist activity of LPSBC and LPSBCAra on hexa-
acylated E. coli LPS was assayed. NF-B activation upon stimulation of HEK293 hTLR4 after 1 h with LPSBC (1, 10, and 100 ng/ml) and LPSBCAra (1, 10, and
100 ng/ml) followed by exposure to E. coli LPS (1 and 10 ng/ml) for 4 h is shown. The data are pooled from three independent experiments done in
triplicate. Bars indicate S.D.; significance was calculated in comparison with stimulation with E. coli LPS (1 and 10 ng/ml) (*, p 0.05; **, p 0.01). NS, no
stimulation.
FIGURE 5. Proinflammatory and endotoxic potential of LPSBC in C57Bl/6 mice. From three to five mice per group were challenged via intraperitoneal
injectionwith300g/mouseLPS from E. coliandP. aeruginosaRP73, LPSBC, andLPSBCAra. TNF- levels in serawerequantifiedafter 5hof treatment. Treatment
with sterile saline solutionwas used as control (Ctrl). The data are pooled from two independent experiments. Bars indicatemean S.D. Statistical analysiswas
made for pair wise comparisons (*, p 0.05; **, p 0.01).
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specific differences in the recognition of lipid IVA between
hMD-2 and mMD-2. We therefore introduced amino acid
replacements at positions 122 and 125 in both MD-2 homo-
logues to test whether the substitutions could affect LA binding
and influence the selectivity of TLR4 activation by the LABC
variants. The E122K replacement in mMD-2 introducing the
equivalent lysine of hMD-2 had little or no effect on the activa-
tion induced by LABC, LABCAra, or the hexa-acylated lipid A.
In contrast, this replacement significantly decreased activation
by lipid IVA (p  0.001; Fig. 7) likely due to removal of the
repulsive forces toward its bisphosphorylated disaccharide
backbone. These repulsive interactions have been proposed to
be important for positioning of lipid IVA in an appropriate ori-
entation for TLR4 dimerization (52). Thus, the unchanged
LABC/LABCAra responsiveness suggests that the single residue
at position 122 of the murine MD-2 protein is not critical for
LABC/LABCAra signaling.
Stimulation of cells expressing the double E122K/L125K
mMD-2 replacement (Fig. 7) showed substantially increased
activity of the mutant MD-2 regardless of the LPS variant
(hexa-acylated lipid A versus hexa-acylated lipid A, p  0.05;
LABC versus LABC, p  0.001; LABCAra versus LABCAra, p 
0.001, respectively, on mTLR4mMD-2 and mTLR4mMD-2
E122K L125K; Fig. 7) except with lipid IVA whose activity was
strongly impaired (p  0.001; Fig. 7). Conversely, hMD-2 in
combination with mTLR4 exhibited significantly stronger acti-
vation by LPSBCAra (p  0.05; Fig. 7), demonstrating that the
L-Ara4N affects interaction with the TLR4 ectodomain. More-
over, the hMD-2 K122E mutant had an additive effect in com-
bination with mTLR4 on the activation induced by LABCAra,
showing an increment of the NF-B activity (LABCAra
mTLR4hMD-2 K122E versus LABCAra hTLR4hMD-2, p 
0.001; LABCAra mTLR4hMD-2 K122E versus LABCAra
mTLR4hMD-2, p  0.05; Fig. 7). This probably reflects the
FIGURE 6. B. cenocepacia LPS acylation pattern is responsible for the NF-B activation. NF-B activation upon stimulation of HEK293 hTLR4hMD-2 after
6 h with LPSBC and LPSBCAra is shown. Stimulation for 6 h with E. coli LPS was used as the control. The same protocol was used to stimulate HEK293
hTLR4hMD-2 V82F cells. The data are pooled from three independent experiments done in triplicate. Bars indicate S.D.; significance was calculated in
comparison with E. coli LPS (*, p 0.05; **, p 0.01; ***, p 0.001). NS, no stimulation.
FIGURE 7. Lys-122 and Lys-125 in the B. cenocepacia LPS signaling on murine and human TLR4MD-2 complexes. An NF-B-luciferase reporter assay
stimulatingHEK293hTLR4hMD-2,HEK293mTLR4mMD-2, andmTLR4hMD-2after 6hwith LPSBC andLPSBCArawas carriedout. Stimulations for 6hwith E. coli
LPS andwith lipid IVAwereusedas controls. The sameprotocolwasused to stimulateHEK293mTLR4mMD-2E1222KandHEK293mTLR4mMD-2E122K/L125K
cells. The data are pooled from two independent experiments done in triplicate. Bars indicate S.D.; statistical analysis was calculated for pairwise comparisons
(*, p 0.05; ***, p 0.001). NS, no stimulation.
Activation of TLR4MD-2 by Burkholderia LPS
21312 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 35•AUGUST 28, 2015
presence of repulsive forces toward the phosphate groups of the
lipid A that might facilitate the orientation toward the Cys-95/
Cys-105 loop (52, 53).
Together, these experiments using hMD-2 and mMD-2
mutants support the notion that the peculiar structure of the
LABC plays a key role in its interaction with MD-2 as well as in
the dimerization process. Our data suggest that the L-Ara4N
molecules on the diglucosamine backbone influence the bind-
ing of lipid A to the TLR4MD-2 complex, although their
absence is not sufficient to impair signaling.
Molecular Modeling of LPSBC Binding to TLR4MD-2—Our
previous results suggested that different MD-2 binding affinities
drive the agonist activity of LPS. To provide amodel for the inter-
actionsofLPSBCandLPSBCAra, dockingcalculationswereunder-
taken, and the two ligands were docked into hMD-2 andmMD-2
proteins. Validation of the docking protocols was performed with
AutoDock and AutoDock Vina by docking E. coli lipid A into the
MD-2 protein from their corresponding crystallographic struc-
tures (Protein Data Bank codes 3fxi (human) and 3vq2 (murine)).
Values of rootmean square deviation and predicted free energy of
binding values indicated an excellent performance of both pro-
grams in predicting the crystallographic binding pose for both
hMD-2 andmMD-2 proteins (Table 1).
LABC and LABCAra were predicted to bind both MD-2 ho-
mologues with binding poses that agreed with the crystallo-
graphic binding poses for E. coli lipid A (superimposition with
E. coli lipid A in Figs. 8 and 9). Docking poses consisted of four
fatty acid chains deeply immersed into the hydrophobic pocket
of MD-2, establishing van der Waals and CH- interactions
with the side chains of most of the lipophilic residues of the
MD-2 pocket, mainly consisting of aliphatic Leu, Ile, and Val
residues; aromatic Phe (numbering 76, 104, 119, 121, 126, 147,
and 151); and Tyr (numbering 102 and 131) residues. All
docked poses were found to participate in hydrophobic inter-
actions with most of these residues. Higher efficiency in estab-
lishing lipophilic interactions can be deduced given the length
of these four fatty acid chains. The fifth chain is placed into the
groove or channel defined byPhe-126, Leu-87,Val-82, andArg-
90. This channel has been identified in the x-ray structures of
the complex of TLR4MD-2 with E. coli lipid A (18) as the allo-
cation site for one lipid chain, allowing completion of the
hydrophobic interface required for dimerization with the sec-
ond TLR4MD-2ligand partner (referred to here as TLR4*
MD-2*). This precludes formation of the activated TLR4MD-
2ligandmultimer. Also Phe-126 has been proposed as a switch
controlling the agonist/antagonist conformation of MD-2
because Phe-126mutation prevents dimerization and abolishes
downstream signaling (18, 53).
Therefore, the model predicts that the greater length of
the five fatty acid chains compared with E. coli lipid A places
the fifth chain outside the MD-2 pocket, thus building the
dimerization interface in the Phe-126, Leu-87, Val-82, and
Arg-90 groove, analogously to the sixth fatty acid of E. coli lipid
A, whereas the other four chains remain inside the MD-2
pocket, providing stabilizing interactions.
Furthermore, the disaccharide scaffolds of LABC and
LABCAra together with the phosphate groups are predicted to
be in the outer region and to establish electrostatic interactions
with the polar residues that define the rim of the MD-2 pocket
FIGURE 8. Predicted bindingmode of the LPSBC core to hTLR4MD-2. The computational model from docking followed by MDS is shown. LPSBC docked to
MD-2 is shown in Corey-Pauling-Koltun colors. Superimposed fatty acids chains from E. coli lipid A are shown in different colors. Some representative residues
from the MD-2 binding site are represented with carbon atoms in green.
TABLE 1
Theoretical free energy of binding for the docking calculations with
AutoDock 4.2 and AutoDock Vina (in bold)
Energy values are in kcal mol1. Root mean square deviation (r.m.s.d.) values are
in Å.
Human MD-2 Murine MD-2
LABC 20.02/25.30 17.73/23.60
LABCAra 18.22/18.60 13.09/17.20
E. coli lipid A 24.41/28.3
(r.m.s.d. 0.282/0.599)
24.73/27.9
(r.m.s.d. 0.647/0.394)
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(Fig. 10). The higher predicted affinity for LPSBC could be
explained in terms of additional anchorage points arising from
the L-Ara4N residues. In particular, these L-Ara4N molecules
can establish additional interactions with MD-2. The hydroxyl
(OH) group from Tyr-102 establishes bridged H-bonding with
theOHat position 2 of L-Ara4N and theOH from the acyl chain
(Fig. 10), whereas OH at position 3 from the same L-Ara4N
establishes a hydrogen bond with the Ser-118 OH group. In the
case of L-Ara4N-2, the OH group from one of the acyl chains
establishes a hydrogen bond with the ys-122 CO group,
whereasOH-3 and ammonium groups, although of theH-bond
distance range (4.5 Å), are well oriented toward carbonyl
groups from Lys-122 and Gly-123 and may enable a putative
H-bond networking at this site. These interactions could also
be identified in the complex with mMD-2 (data not shown).
This predicted binding mode of LABC could thus explain the
unexpected significant level of activation in the biological
assays. The lack of some lipophilic interactions arising from the
absent sixth fatty acid chain in comparison with E. coli lipid A
could also be counterbalanced by these extra polar interactions
from the L-Ara4N residues.
Molecular Model of the hTLR4MD-2 dimer in Complex with
LPSBC—To develop a structural model for the TLR4MD-2
dimer in complex with LPSBC, we first docked the inner core
oligosaccharide moiety of LPSBC (Fig. 1) on hTLR4 using as a
guide the region where E. coli LPS inner core binds. The best
binding pose was selected (theoretical binding free energy of
2.8 kcal mol1 by AutoDock Vina) taking also into account a
proper orientation for the building of the full complex. The
docked pose superimposed with E. coli LPS core from Protein
Data Bank code 3fxi is shown in Fig. 11. The hTLR4core com-
plex was then assembled to the MD-2LABC complex (best
result from AutoDock Vina calculations), leading to a full
hTLR4MD-2LPSBC complex. The receptor dimer was built
using Protein Data Bank code 3fxi as a template. The full three-
dimensional structure of the dimer complex (Fig. 12) was sub-
jected toMDS,which did not showmeaningful differenceswith
the docked complexes (data not shown). The three-dimen-
sional model of the full complex supports the key interactions
for the molecular recognition of LPSBC that were described
above and also confirms that the L-Ara4N residues (including
the one present in the LPS core region; Fig. 1) play a fundamen-
tal role in the complex formation as they participate inH-bond-
ing at the dimerization interfaces (Fig. 13). First, both ammo-
nium groups from L-Ara4N-2 and -3 (Fig. 13) (this latter is
attached to a D-glycero-D-talo-2-octulosonic acid in the core
moiety; Fig. 1) establish hydrogen bonds with the TLR4 Arg-
264 and Asp-294 carboxylate groups. Second, the ammonium
group of L-Ara4N-1 is close to the Asp-395 carboxylate and the
Ser-416OH group, which belong to the opposite TLR4*. Third,
the OH-3 from L-Ara4N-1 establishes an H-bond with the Ser-
415 CO group of TLR4* (Fig. 13). The three-dimensional mod-
els from docking could suggest higher activation for LPSBC ver-
sus LPSBCAra arising from the extra anchorage points from
FIGURE 9. Predicted binding mode of the LPSBC core to hTLR4MD-2. Details of LPSBC (Corey-Pauling-Koltun colors) docked to MD-2 are shown. Superim-
posed fatty acids chains from E. coli lipid A are shown with carbon atoms in blue.
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arabinoses. This agrees with the higher endotoxic potential of
LPSBC in the biological assays. Based on thisTLR4MD-2LPSBC
model, we built a newmodel with the following fourmutations:
D294A, R322A, S415A*, and S416A*. These mutations involve
the main residues establishing interactions with the ammo-
nium groups from the three Ara4N residues and the OH group
from the terminal glucose (Fig. 13). (i) Asp-294 side chain
establishes polar interactions reinforced by hydrogen bonds
with the ammonium group from Ara4N-3, and is in the prox-
imity of the ammonium group from Ara4N-2, so this residue
can be considered as a main anchorage point for TLR4MD-
2LPSBC; Asp-294 was mutated to Ala to abolish this interac-
tion. (ii) Ser-415* and Ser-416* are placed in the partner TLR4*
and provide an anchorage point for the ammonium group from
Ara4N-1 through polar interactions with the side chain of Ser-
415* and the backbone CO groups; both Ser residues were
mutated toAla. (iii) Although not directly in contactwith any of
theAra4Nmoieties, theArg-322 side chain establishes a hydro-
gen bond with the OH group at position 3 from the terminal
glucose, and we mutated it to compare its contribution to the
global energy of the system; this interaction is absent in the
complex of TLR4MD-2 with E. coli LPS (Protein Data Bank
code 3fxi) and could be considered as a distinctive interaction
for LPSBC core. MDS and energy calculations of both systems
(TLR4MD-2LPSBC and mutant TLR4MD-2LPSBC) have
shown an important difference in the global energy: the wild
type complex (TLR4MD-2LPSBC model) is around 32 kcal
mol1 more stable than the mutant counterpart mainly due to
the coulombic term, pointing to the presence of important
polar interactions (Table 2). Analysis of the contributions of
each residue to the ligand binding energy reveals that this
energy difference is mainly due to the lack of the interactions
involving the mutated residues. (i) Interaction with Asp-294 is
the strongest interaction in the TLR4MD-2LPSBC system
(around 22 kcalmol1) and is absent in themutant. (ii) Also the
interaction with Arg-322 is missing; this is one of the main
interactions in the TLR4MD-2LPSBC system (around 9.6 kcal
mol1). (iii) The lower coulombic contribution to the interac-
tion energy in themutant TLR4MD-2LPSBC complex is due to
the absence of the interaction between the Ser-415* side chain
and the ammonium group. These results give reasonable evi-
dence that the Ara4N ammonium groups provide additional
anchorage interactions accounting for the final stability of the
TLR4MD-2LPSBC complex. Abolishing these interactions
FIGURE 10. Predicted binding mode of the LPSBC core to hTLR4MD-2. Detail of some H-bond interactions between the LPSBC inner core and TLR4MD-2
involving Tyr-102 is shown. LPSBC is represented in Corey-Pauling-Koltun colors, and MD-2 protein is represented in green.
FIGURE 11. Superimposition of best dock results of LPSBC core. The dock-
ing was obtained using AutoDock Vina (depicted in red) and E. coli LPS core
fromProteinDataBankcode3fxi (depicted ingreen). TLR4 isnot shown for the
sake of clarity.
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leads to a less stable complex, suggesting that they are crucial
for the binding.
Discussion
Lipid A is a major determinant of cytokine induction in host
immune cells (11–19, 54). Generally, the highest immunos-
timulatory activity of lipid A correlates with its hexa-acylation
pattern (11–19, 54) because the sixth acyl chain protrudes from
the MD-2 binding pocket, bridging TLR4MD-2 complex
dimerization.On the contrary, underacylated lipidAmolecules
are not (or are poorly) sensed by humanTLR4MD-2 as they are
potentially accommodated within the MD-2 pocket. Here, we
demonstrate a role for L-Ara4N residues in lipid A that explains
why theB. cenocepacia LPS (naturally consisting of amixture of
penta- and tetra-acylated forms) acts as a strong TLR4MD-2
agonist. Our results agree with a recent report by Hollaus et al.
(36) demonstrating that a synthetic Burkholderia lipid A sub-
stituted with L-Ara4N exclusively at the anomeric phosphate
acts as a potent human TLR4MD-2 agonist.
Our in vitro and in vivo results explain and expand the above
conclusions and show that B. cenocepacia penta-acylated lipid
A (both LABC and LABCAra) elicits an inflammatory response
activating the TLR4MD-2 complex, suggesting that the model
of the receptor complex activation should also include other
structural components. Furthermore, molecular modeling
experiments indicated that the increased length of the two
amide-linked acyl chains of the B. cenocepacia lipid A moiety
(3-(R)-hydroxyhexadecanoic acid C16:0 (3-OH) versus 3-(R)-
hydroxytetradecanoic acid C14:0 (3-OH) from the E. coli lipid
A) compensates for the lack of one fatty acid chain filling the
hydrophobic binding pocket of MD-2 protein, allowing the
placement into the channel of the fifth acyl chain responsible
for TLR4 dimerization. The replacement in E. coli lipid A of
the secondary dodecanoic acid C12:0 with a hexadecanoic acid
C16:0 results in a weaker LPS agonist (55). However, our data
indicate that not only the increased length of the acyl chain but
also its position is important for agonist activity.
Furthermore, our mutagenesis studies using two B. cenoce-
pacia lipidA forms, LABC and LABCAra, uncovered differential
responsiveness on transfected HEK293 cells, indicating an
important role also for the L-Ara4N residues in the TLR4LABC
binding process. Particularly, the significantly different immu-
FIGURE 12. Predicted binding mode of the LPSBC core to hTLR4MD-2. The computational model from docking followed by MDS is shown. Left panel,
three-dimensionalmodel of thedimer of LPSBC core in complexwith TLR4MD-2.Right panel, detail of thedimer of LPSBC inner core in complexwith TLR4MD-2.
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nostimulatory activity of LABC compared with LABCAra (Fig.
7) observed in the presence of the human MD-2 K122E muta-
tionmight be related to the occurrence on LABC of the L-Ara4N
residues, which could mask the negatively charged phosphate
groups and then reduce the repulsive forces introduced with
the K122E mutation. In contrast, the absence of L-Ara4N in
LABCAra might explain its increased agonistic activity when
tested onHEK293 cells transfectedwithmTLR4hMD-2K122E
because the repulsive forces introducedmight facilitate the ori-
entation toward the Cys-95/Cys-105 loop (52, 53). Therefore, it
is reasonable to assume that the L-Ara4N modification with its
positively charged ammonium group could favor the electro-
static interactions allowing receptor/lipid A binding. Intrigu-
ingly, recent work by Maeshima et al. (56) revealed several key
charged amino acid residues in TLR4 and MD-2 mediating
host-specific responses to the glucosamine-modified penta-
acylated lipid A from Bordetella pertussis and its unmodified
counterpart by human and mouse TLR4MD-2 complexes.
This further underscores the importance of positively charged
residues decorating penta-acylated lipid A and interacting with
human TLR4MD-2 charged amino acid residues to promote
complex activation (56).
Our molecular modeling experiments further supported the
notion that L-Ara4N residues provide additional polar interac-
tions affecting the LABC binding to the TLR4MD-2 and con-
tribute to anchoring the lipid A into the receptor complex. The
network of hydrogen bonds and polar interactions contributing
to anchoring the lipid A into the TLR4MD-2 involves not only
the sugar residues from the core oligosaccharide (for example,
hydrogen bonds involving Arg-322; Fig. 13) but also the three
FIGURE 13. Predicted binding mode of the LPSBC core to hTLR4MD-2.
Details of some interactions between the LPSBC inner core and TLR4MD-2
from the computational model are shown.
TABLE 2
Analysis of the per residue contributions to the total ligand binding energy for both complexes TLR4MD-2LPSBC and the mutated TLR4MD-
2LPSBC (D294A, R322A, S415A*, and S416A*)
Energy calculations come from the MDS. Only the top 22 contributions are shown (top 20 in the case of the mutant). Residues from TLR4 are underlined. Residues from
the partner TLR4 are also marked with *. vdW, van der Waals; Desolv, desolvated.
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L-Ara4N residues and the partner TLR4*. As stated above,
mutagenesis studies demonstrate that several Lys residues
involved in LPS binding play indispensable roles through the
polar interactions with the phosphate groups (56–59). In our
dimer model, Lys-122 is involved in binding the lipid A moiety
of the LPSBC through polar interactions with the core; as for
V82F, its role in building the groove that accommodates the
acyl chain from lipid A, completing the interaction surface
required for dimerization, has already been mentioned. The
replacement of Val-82 by phenylalanine involves changes of
van der Waals interactions into CH- interactions, which may
favor the binding of this chain, which is longer than the corre-
sponding chain on E. coli LPS. Thus, the structural peculiarities
of B. cenocepacia, i.e. its acylation pattern and the presence of
the L-Ara4N residues in the lipid A region, exert a synergistic
effect in the activation and dimerization of the LPS receptor,
opening new insights into the comprehension of the molecular
recognition of LPS by TLR4MD-2.
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